TG Therapeutics Inc.(TGTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TGTX TG Therapeutics Inc.

已收盘 02-25 16:00:00 EST

29.66

-0.85

-2.79%

盘后29.94

+0.28+0.93%

19:11 EST

最高30.72	最低29.64	成交量238.45万
今开30.29	昨收30.51	日振幅3.54%
总市值47.09亿	流通市值43.90亿	总股本1.59亿
成交额7,153万	换手率1.61%	流通股本1.48亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TGTX","market":"US","secType":"STK","nameCN":"TG Therapeutics Inc.","latestPrice":29.66,"timestamp":1772053200000,"preClose":30.51,"halted":0,"volume":2384513,"hourTrading":{"tag":"盘后","latestPrice":29.9351,"preClose":29.66,"latestTime":"19:11 EST","volume":317694,"amount":9424467.9435,"timestamp":1772064665739,"change":0.2751,"changeRate":0.009275,"amplitude":0.009413},"delay":0,"changeRate":-0.027859718125204897,"floatShares":148000000,"shares":158759451,"eps":2.776003,"marketStatus":"已收盘","change":-0.85,"latestTime":"02-25 16:00:00 EST","open":30.29,"high":30.72,"low":29.64,"amount":71533088.94495499,"amplitude":0.035398,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.776003,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1772096400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1128657600000,"exchange":"NASDAQ","adjPreClose":30.51,"preHourTrading":{"tag":"盘前","latestPrice":30.29,"preClose":30.51,"latestTime":"09:27 EST","volume":590,"amount":17916.6008,"timestamp":1772029660058,"change":-0.22,"changeRate":-0.007211,"amplitude":0.007211},"postHourTrading":{"tag":"盘后","latestPrice":29.9351,"preClose":29.66,"latestTime":"19:11 EST","volume":317694,"amount":9424467.9435,"timestamp":1772064665739,"change":0.2751,"changeRate":0.009275,"amplitude":0.009413},"volumeRatio":1.763621,"impliedVol":0.6764,"impliedVolPercentile":0.5418},"requestUrl":"/m/hq/s/TGTX","defaultTab":"news","newsList":[{"id":"1111244728","title":"TG Therapeutics携手克里斯蒂娜·艾伯盖特推动多发性硬化症疾病认知普及","url":"https://stock-news.laohu8.com/highlight/detail?id=1111244728","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111244728?lang=zh_cn&edition=full","pubTime":"2026-02-09 05:18","pubTimestamp":1770585490,"startTime":"0","endTime":"0","summary":"生物制药公司TG Therapeutics近日宣布，将与知名演员克里斯蒂娜·艾伯盖特展开深度合作，共同致力于提升公众对多发性硬化症的认知水平。此次合作旨在通过名人影响力扩大疾病科普覆盖面，帮助患者群体获得更广泛的社会支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","TGTX","BK4585"],"gpt_icon":0},{"id":"1132472380","title":"TG Therapeutics公布Briumvi®（Ublituximab）多发性硬化症数据亮相美洲多发性硬化症治疗与研究委员会年度论坛","url":"https://stock-news.laohu8.com/highlight/detail?id=1132472380","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132472380?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:31","pubTimestamp":1770381080,"startTime":"0","endTime":"0","summary":"TG Therapeutics公司宣布，其针对多发性硬化症的创新药物Briumvi®（Ublituximab）的最新临床数据，将在美洲多发性硬化症治疗与研究委员会（ACTRIMS）年度论坛上进行专题报告。此次展示将涵盖该药物的疗效持久性、安全性特征及对患者生活质量的影响等多维度研究结果，为医学界提供更全面的治疗参考依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4139","TGTX"],"gpt_icon":0},{"id":"1112173479","title":"TG Therapeutics公布Briumvi®治疗多发性硬化症数据在美洲多发性硬化症治疗与研究委员会年会上的展示日程","url":"https://stock-news.laohu8.com/highlight/detail?id=1112173479","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112173479?lang=zh_cn&edition=full","pubTime":"2026-01-27 20:32","pubTimestamp":1769517120,"startTime":"0","endTime":"0","summary":"TG Therapeutics公司近日宣布，其旗下药物Briumvi针对多发性硬化症的研究数据将在美洲多发性硬化症治疗与研究委员会年度论坛上进行系列展示。相关展示日程已正式确定。Briumvi作为一种创新疗法，其临床数据备受业界关注。TG Therapeutics此次公布展示安排，标志着该药物在多发性硬化症治疗领域的研究进入新阶段。公司表示，这些数据展示将涵盖Briumvi在多发性硬化症治疗中的有效性、安全性及最新临床研究成果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGTX","BK4139","BK4588","BK4585"],"gpt_icon":0},{"id":"1166654438","title":"TG Therapeutics股价创去年11月以来新高，初步2025年销售额超预期，收盘大涨12.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166654438","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166654438?lang=zh_cn&edition=full","pubTime":"2026-01-14 22:44","pubTimestamp":1768401886,"startTime":"0","endTime":"0","summary":"TG Therapeutics Inc. (TGTX) 股价今日强势攀升，收盘录得12.9%的可观涨幅，创下去年11月以来的最高水平。此番强劲表现主要得益于公司发布的初步数据显示，其2025年的销售额预期已超越市场共识。\n市场对这家生物技术公司的前景展现出浓厚兴趣，投资者情绪受到积极销售指引的显著提振。股价的飞跃反映出市场对其未来增长潜力的重新评估和坚定信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TGTX","BK4585","BK4588"],"gpt_icon":0},{"id":"1104121370","title":"TG Therapeutics盘初大涨18%，2025销售业绩超预期，2026营收指引乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1104121370","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104121370?lang=zh_cn&edition=full","pubTime":"2026-01-14 22:34","pubTimestamp":1768401285,"startTime":"0","endTime":"0","summary":"显示出对未来增长的乐观预期。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGTX"],"gpt_icon":0},{"id":"1133474703","title":"异动解读 | 初步销售额超预期及2026年营收指引乐观，TG Therapeutics盘前大涨7.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=1133474703","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133474703?lang=zh_cn&edition=full","pubTime":"2026-01-14 18:14","pubTimestamp":1768385685,"startTime":"0","endTime":"0","summary":"TG Therapeutics Inc.（TGTX）今日盘前大涨7.18%，股价表现强劲。消息面上，公司公布的2025年初步净销售额为6.16亿美元，超出此前预期的6亿美元。同时，公司对2026年的营收指引为8.75亿至9亿美元，显示出对未来增长的乐观预期。公司首席执行官Michael Weiss表示，若多发性硬化症药物Briumvi获得批准，新的静脉输注计划有望短期内提升收入，进一步增强了市场信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TGTX"],"gpt_icon":0},{"id":"1178336933","title":"异动解读 | 初步销售额超预期及2026年营收指引乐观，TG Therapeutics夜盘大涨7.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=1178336933","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178336933?lang=zh_cn&edition=full","pubTime":"2026-01-14 16:40","pubTimestamp":1768380055,"startTime":"0","endTime":"0","summary":"TG Therapeutics Inc.（TGTX）今日夜盘大涨7.61%，股价表现强劲。消息面上，公司公布的2025年初步净销售额为6.16亿美元，超出此前预期的6亿美元。同时，公司对2026年的营收指引为8.75亿至9亿美元，显示出对未来增长的乐观预期。公司首席执行官Michael Weiss表示，若多发性硬化症药物Briumvi获得批准，新的静脉输注计划有望短期内提升收入，进一步增强了市场信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TGTX"],"gpt_icon":0},{"id":"1150259462","title":"TG Therapeutics公布2025年第四季度及全年初步净产品收入、2026年营收指引与预期研发里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1150259462","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150259462?lang=zh_cn&edition=full","pubTime":"2026-01-14 05:26","pubTimestamp":1768339575,"startTime":"0","endTime":"0","summary":"TG Therapeutics Inc.披露了2025年第四季度及全年的初步净产品收入数据，同时公布了2026年的营收预期指引以及公司计划达成的关键研发里程碑。这些信息反映了公司在商业化进程和研发管线推进方面的最新进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TGTX","BK4588","BK4585"],"gpt_icon":0},{"id":"1152917435","title":"TG Therapeutics完成Briumvi新简化给药方案的三期Enhance试验的入组工作","url":"https://stock-news.laohu8.com/highlight/detail?id=1152917435","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152917435?lang=zh_cn&edition=full","pubTime":"2025-10-28 19:31","pubTimestamp":1761651075,"startTime":"0","endTime":"0","summary":"TG Therapeutics完成了关于其新简化给药方案Briumvi的三期Enhance试验的入组工作","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGTX","BK4585","BK4139","BK4588"],"gpt_icon":0},{"id":"1142145272","title":"TG Therapeutics宣布将在2025年欧洲多发性硬化症治疗和研究委员会年会上公布Briumvi®多发性硬化症数据展示安排","url":"https://stock-news.laohu8.com/highlight/detail?id=1142145272","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142145272?lang=zh_cn&edition=full","pubTime":"2025-09-10 19:31","pubTimestamp":1757503884,"startTime":"0","endTime":"0","summary":"TG Therapeutics宣布将在2025年欧洲多发性硬化症治疗和研究委员会年会上公布Briumvi®多发性硬化症数据展示安排","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TGTX","BK4139","BK4588","BK4585"],"gpt_icon":0},{"id":"1153229280","title":"TG Therapeutics宣布完成现有股份回购计划并授权新的1亿美元回购方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1153229280","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153229280?lang=zh_cn&edition=full","pubTime":"2025-09-03 19:30","pubTimestamp":1756899033,"startTime":"0","endTime":"0","summary":"TG Therapeutics宣布已完成现有股份回购计划的执行，同时获得董事会授权启动新的1亿美元股份回购方案。\n该公司表示，此次新的股份回购计划将为公司提供更多资本配置的灵活性，体现了管理层对公司长期发展前景的信心。新的1亿美元回购授权将使公司能够根据市场条件和业务需要，适时回购公司股份。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","TGTX","BK4139","BK4585"],"gpt_icon":0},{"id":"2518744086","title":"Tg Therapeutics, Inc.2024财年实现净利润23.38百万美元，同比增加84.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518744086","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518744086?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:01","pubTimestamp":1741449668,"startTime":"0","endTime":"0","summary":"3月9日，Tg Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为23.38百万美元，同比增加84.53%；其中营业收入为3.29亿美元，同比增加40.60%，每股基本收益为0.16美元。机构评级：截至2025年3月9日，当前有6家机构对Tg Therapeutics, Inc.目标价做出预测，其中目标均价为42.83美元，其中最低目标价为10.00美元，最高目标价为55.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000230a266b3d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000230a266b3d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","TGTX"],"gpt_icon":0},{"id":"2517162677","title":"Tg Therapeutics, Inc.盘中异动 股价大涨5.04%报36.88美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517162677","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517162677?lang=zh_cn&edition=full","pubTime":"2025-03-07 00:04","pubTimestamp":1741277052,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日00时04分，Tg Therapeutics, Inc.股票出现波动，股价快速拉升5.04%。截至发稿，该股报36.88美元/股，成交量108.177万股，换手率0.69%，振幅6.61%。Tg Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.38%。Tg Therapeutics, Inc.公司简介：TG Therapeutics Inc 是一家完全整合的，商业阶段生物制药公司，专注于 B 细胞疾病新型疗法的获得、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000412989ec607&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000412989ec607&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4588","BK4139","TGTX","BK4585"],"gpt_icon":0},{"id":"2516711677","title":"Tg Therapeutics, Inc.盘中异动 股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516711677","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516711677?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:37","pubTimestamp":1741099069,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时37分，Tg Therapeutics, Inc.股票出现波动，股价急速拉升5.00%。Tg Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.09%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Protagenic Therapeutics, Inc.、Capricor Therapeutics, Inc.涨幅较大，Aeon Biopharma, Inc.、Windtree Therapeutics, Inc.、Protagenic Therapeutics, Inc.较为活跃，换手率分别为1090.78%、1079.98%、427.26%，振幅较大的相关个股有Celularity Inc C/Wts 16/07/2026 、Hepion Pharmaceuticals, Inc.、Pliant Therapeutics, Inc.，振幅分别为23.30%、22.25%、14.49%。Tg Therapeutics, Inc.公司简介：TG Therapeutics Inc 是一家完全整合的，商业阶段生物制药公司，专注于 B 细胞疾病新型疗法的获得、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223749abe7f1dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223749abe7f1dd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TGTX","LENZ","BK4588","BK4585"],"gpt_icon":0},{"id":"1131727124","title":"TG Therapeutics 2024年第四季度GAAP每股收益$0.15，与预期一致，销售额$108.19M超$99.95M预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1131727124","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131727124?lang=zh_cn&edition=full","pubTime":"2025-03-03 20:13","pubTimestamp":1741004021,"startTime":"0","endTime":"0","summary":"TG Therapeutics公布季度每股收益为$0.15，符合分析师的一致预期。公司本季度销售额为$108.19百万，超过分析师预期的$99.95百万，超出8.24%。与去年同期的$43.97百万销售额相比，这是一个146.04%的增长。以上内容来自Benzinga Earnings专栏，原文如下：TG $Therapeutics$  reported quarterly earnings of $0.15 per share which met the analyst consensus estimate. This is a 250 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $108.19 million which beat the analyst consensus estimate of $99.95 million by 8.24 percent.  This is a 146.04","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TG","TGTX"],"gpt_icon":0},{"id":"2516301606","title":"Tg Therapeutics, Inc.盘中异动 临近收盘股价大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516301606","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516301606?lang=zh_cn&edition=full","pubTime":"2025-03-01 04:50","pubTimestamp":1740775803,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日04时50分，Tg Therapeutics, Inc.股票出现异动，股价急速拉升5.01%。Tg Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.82%。Tg Therapeutics, Inc.公司简介：TG Therapeutics Inc 是一家完全整合的，商业阶段生物制药公司，专注于 B 细胞疾病新型疗法的获得、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301045003abe13d94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301045003abe13d94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TGTX","LENZ","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"2514703346","title":"Tg Therapeutics, Inc.盘中异动 下午盘股价大跌5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514703346","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514703346?lang=zh_cn&edition=full","pubTime":"2025-02-25 04:22","pubTimestamp":1740428567,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日04时22分，Tg Therapeutics, Inc.股票出现波动，股价大幅跳水5.12%。Tg Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.21%。其相关个股中，Nutriband Inc C/Wts 、Pepgen Inc.、Surrozen Inc C/Wts 01/08/2031 涨幅较大，Pepgen Inc.、Aditxt, Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为327.09%、142.18%、41.18%，振幅较大的相关个股有Nutriband Inc C/Wts 、Pepgen Inc.、Surrozen Inc C/Wts 01/08/2031 ，振幅分别为176.22%、162.04%、81.92%。Tg Therapeutics, Inc.公司简介：TG Therapeutics Inc 是一家完全整合的，商业阶段生物制药公司，专注于 B 细胞疾病新型疗法的获得、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022504224798913a0e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022504224798913a0e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4585","TGTX","BK4588","LENZ"],"gpt_icon":0},{"id":"2508997936","title":"Tg Therapeutics, Inc.盘中异动 临近收盘股价大跌5.01%报31.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508997936","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508997936?lang=zh_cn&edition=full","pubTime":"2025-02-01 04:54","pubTimestamp":1738356887,"startTime":"0","endTime":"0","summary":"北京时间2025年02月01日04时54分，Tg Therapeutics, Inc.股票出现异动，股价快速跳水5.01%。Tg Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.60%。Tg Therapeutics, Inc.公司简介：TG Therapeutics Inc 是一家完全整合的，商业阶段生物制药公司，专注于 B 细胞疾病新型疗法的获得、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250201045447a2358435&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250201045447a2358435&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4588","BK4139","BK4585","TGTX"],"gpt_icon":0},{"id":"2506309359","title":"Tg Therapeutics, Inc.盘中异动 早盘急速拉升5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2506309359","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506309359?lang=zh_cn&edition=full","pubTime":"2025-01-27 23:24","pubTimestamp":1737991499,"startTime":"0","endTime":"0","summary":"北京时间2025年01月27日23时24分，Tg Therapeutics, Inc.股票出现波动，股价急速拉升5.05%。Tg Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.32%。其相关个股中，Akero Therapeutics, Inc.、Onconetix, Inc.、89Bio, Inc.涨幅较大，Onconetix, Inc.、Dogwood Therapeutics, Inc.、Evaxion Biotech As较为活跃，换手率分别为1801.77%、202.36%、197.33%，振幅较大的相关个股有Onconetix, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Dogwood Therapeutics, Inc.，振幅分别为85.35%、65.16%、61.84%。Tg Therapeutics, Inc.公司简介：TG Therapeutics Inc 是一家完全整合的，商业阶段生物制药公司，专注于 B 细胞疾病新型疗法的获得、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127232459961241f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127232459961241f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4585","BK4588","TGTX","BK4139"],"gpt_icon":0},{"id":"2506941228","title":"Tg Therapeutics, Inc.盘中异动 股价大涨5.03%报30.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506941228","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506941228?lang=zh_cn&edition=full","pubTime":"2025-01-25 02:55","pubTimestamp":1737744942,"startTime":"0","endTime":"0","summary":"北京时间2025年01月25日02时55分，Tg Therapeutics, Inc.股票出现异动，股价快速上涨5.03%。Tg Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.15%。其相关个股中，Celularity Inc C/Wts 16/07/2026 、Neuphoria Therapeutics Inc.、Dermata Therapeutics Inc C/Wts 涨幅较大，Evaxion Biotech As、Pmgc Holdings Inc.、Transcode Therapeutics, Inc.较为活跃，换手率分别为4273.07%、2353.10%、1709.92%，振幅较大的相关个股有Neuphoria Therapeutics Inc.、Celularity Inc C/Wts 16/07/2026 、Evaxion Biotech As，振幅分别为261.67%、185.76%、137.09%。Tg Therapeutics, Inc.公司简介：TG Therapeutics Inc 是一家完全整合的，商业阶段生物制药公司，专注于 B 细胞疾病新型疗法的获得、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250125025542a22e91e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250125025542a22e91e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LENZ","BK4585","TGTX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tgtherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0499},{"period":"1month","weight":-0.0221},{"period":"3month","weight":-0.0868},{"period":"6month","weight":0.0535},{"period":"1year","weight":0.0513},{"period":"ytd","weight":0.0235}],"compareEarnings":[{"period":"1week","weight":0.0066},{"period":"1month","weight":-0.0027},{"period":"3month","weight":0.0113},{"period":"6month","weight":0.0592},{"period":"1year","weight":0.1509},{"period":"ytd","weight":0.008}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"TG Therapeutics, Inc.于1993年在特拉华州注册成立。该公司是一家完全整合的、商业化阶段的生物制药公司，专注于B细胞介导疾病新疗法的收购、开发和商业化。其产品BRIUMVI（ublituximab-xiiy）已获得美国、欧盟和英国的监管批准，用于治疗复发性多发性硬化症成人患者。","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":0.050204},{"month":2,"riseRate":0.692308,"avgChangeRate":0.072548},{"month":3,"riseRate":0.666667,"avgChangeRate":0.113076},{"month":4,"riseRate":0.416667,"avgChangeRate":0.02059},{"month":5,"riseRate":0.5,"avgChangeRate":-0.003449},{"month":6,"riseRate":0.538462,"avgChangeRate":0.05525},{"month":7,"riseRate":0.384615,"avgChangeRate":-0.001846},{"month":8,"riseRate":0.538462,"avgChangeRate":-0.030643},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.032476},{"month":10,"riseRate":0.307692,"avgChangeRate":-0.061104},{"month":11,"riseRate":0.846154,"avgChangeRate":0.172847},{"month":12,"riseRate":0.461538,"avgChangeRate":0.09546}],"exchange":"NASDAQ","name":"TG Therapeutics Inc.","nameEN":"TG Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"TG Therapeutics Inc.(TGTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供TG Therapeutics Inc.(TGTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"TG Therapeutics Inc.,TGTX,TG Therapeutics Inc.股票,TG Therapeutics Inc.股票老虎,TG Therapeutics Inc.股票老虎国际,TG Therapeutics Inc.行情,TG Therapeutics Inc.股票行情,TG Therapeutics Inc.股价,TG Therapeutics Inc.股市,TG Therapeutics Inc.股票价格,TG Therapeutics Inc.股票交易,TG Therapeutics Inc.股票购买,TG Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"TG Therapeutics Inc.(TGTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供TG Therapeutics Inc.(TGTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}